GlaxoSmithKline Consumer Nigeria Plc Reports Earnings Results for the Third Quarter and Nine Months of 2017; Provides Earnings Guidance for the Year 2017
For the nine months, the company reported turnover of £22,547 million compared to £20,303 million a year ago. Operating profit was £3,575 million compared to £2,003 million a year ago. Profit before taxation was £3,083 million compared to £1,516 million a year ago. Profit after taxations for the period was £2,532 million compared to £745 million a year ago. Profit attributable to shareholders was £2,078 million compared to £655 million a year ago. Diluted earnings per share were 42.1 pence compared to 13.4 pence a year ago. Net cash inflow from operating activities was £4,049 million compared to £3,506 million a year ago. Purchase of property, plant and equipment was £1,011 million compared to £943 million a year ago. Purchase of intangible assets was £513 million compared to £648 million a year ago. Adjusted operating profit was £6,530 million. Adjusted earnings per share were 84.6 pence. Free cash flow was £1,644 million.
The company earnings guidance for 2017, the company expects adjusted earnings per share growth maintained at 3% to 5% CER.